NZ611316A - Histone inhibition - Google Patents

Histone inhibition

Info

Publication number
NZ611316A
NZ611316A NZ611316A NZ61131611A NZ611316A NZ 611316 A NZ611316 A NZ 611316A NZ 611316 A NZ611316 A NZ 611316A NZ 61131611 A NZ61131611 A NZ 61131611A NZ 611316 A NZ611316 A NZ 611316A
Authority
NZ
New Zealand
Prior art keywords
monosaccharide
optionally substituted
cyclic
polyanion
deoxy
Prior art date
Application number
NZ611316A
Other languages
English (en)
Inventor
Ross Wentworth Stephens
Christopher Richard Parish
Craig Geoffrey Freeman
Timothy John Senden
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Australian filed Critical Univ Australian
Publication of NZ611316A publication Critical patent/NZ611316A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NZ611316A 2010-12-01 2011-11-29 Histone inhibition NZ611316A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41882610P 2010-12-01 2010-12-01
PCT/AU2011/001550 WO2012071611A1 (en) 2010-12-01 2011-11-29 Histone inhibition

Publications (1)

Publication Number Publication Date
NZ611316A true NZ611316A (en) 2014-12-24

Family

ID=46171086

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ611316A NZ611316A (en) 2010-12-01 2011-11-29 Histone inhibition

Country Status (15)

Country Link
US (1) US9226939B2 (enExample)
EP (1) EP2646037B1 (enExample)
JP (2) JP2014501730A (enExample)
KR (1) KR101956335B1 (enExample)
CN (1) CN103402526B (enExample)
AU (1) AU2011335881B2 (enExample)
BR (1) BR112013013544B1 (enExample)
CA (1) CA2819642C (enExample)
DK (1) DK2646037T3 (enExample)
ES (1) ES2710857T3 (enExample)
HU (1) HUE043546T2 (enExample)
IL (1) IL226667A (enExample)
NZ (1) NZ611316A (enExample)
SG (1) SG190438A1 (enExample)
WO (1) WO2012071611A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105593B2 (ja) 1991-10-18 2000-11-06 東海パルプ株式会社 パルパー制御装置
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
US11628179B2 (en) * 2017-12-15 2023-04-18 The Australian National University Compounds for treating and preventing extracellular histone mediated pathologies
WO2019246264A1 (en) * 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2020033824A1 (en) * 2018-08-09 2020-02-13 University Of Vermont And State Agricultural College Inhibitors of acute severe inflammatory conditions
CA3130405A1 (en) * 2019-02-25 2020-09-03 The Australian National University Compounds for treating and preventing net associated complications
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
WO2022116981A1 (zh) * 2020-12-01 2022-06-09 远大医药（中国）有限公司 一种聚阴离子纤维二糖苷类化合物的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5583121A (en) 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
DE69514059T2 (de) 1994-09-21 2000-05-25 Allrad No. 19 Pty Ltd., Canberra Eine elektrostatische Niederschlagsvorrichtung
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
WO1999004826A1 (en) 1997-07-24 1999-02-04 The Australian National University Method for detection of fibrin clots
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
WO2006015171A2 (en) * 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
PT1877105E (pt) 2005-04-29 2013-11-11 Univ Australian Método para formar uma composição radioativa injetável de partículas radioativas encapsuladas em carbono
EP1747785A1 (en) * 2005-07-28 2007-01-31 Istituto Clinico Humanitas Cyclodextrins for blood detoxification
WO2007062403A2 (en) 2005-11-28 2007-05-31 Vernon D Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
EP2209485B1 (en) 2007-11-06 2016-03-30 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
JP5645085B2 (ja) 2008-04-24 2014-12-24 ジ オーストラリアン ナショナル ユニバーシティー マクロ分子を放射性標識化するための方法
JP2011256111A (ja) * 2008-10-03 2011-12-22 Hayashibara Biochem Lab Inc 敗血症の予防及び治療剤

Also Published As

Publication number Publication date
BR112013013544B1 (pt) 2020-09-29
KR20130121877A (ko) 2013-11-06
WO2012071611A1 (en) 2012-06-07
JP2014501730A (ja) 2014-01-23
US9226939B2 (en) 2016-01-05
EP2646037B1 (en) 2019-01-09
IL226667A (en) 2017-02-28
SG190438A1 (en) 2013-07-31
KR101956335B1 (ko) 2019-03-08
ES2710857T3 (es) 2019-04-29
JP2016193917A (ja) 2016-11-17
BR112013013544A2 (pt) 2016-10-11
DK2646037T3 (en) 2019-03-04
JP6142039B2 (ja) 2017-06-07
AU2011335881A1 (en) 2013-06-20
HUE043546T2 (hu) 2019-08-28
CN103402526A (zh) 2013-11-20
CA2819642A1 (en) 2012-06-07
CA2819642C (en) 2019-07-16
AU2011335881B2 (en) 2016-07-14
CN103402526B (zh) 2016-01-20
US20130338097A1 (en) 2013-12-19
EP2646037A1 (en) 2013-10-09
EP2646037A4 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
MX338213B (es) Derivados de oligosacaridos sulfatados novedosos.
PH12013500473A1 (en) Triazine-oxadiazoles
MY184985A (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
PH12013500472A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
MX356010B (es) Compuestos 2-anilino-benzimidazol-6carboxamidas como agentes anti-inflamatorios inhibidores de la prostaglandina e2 sintasa-1 microsómica (mpges-1).
WO2011044501A3 (en) Antibacterial aminoglycoside analogs
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
MX2015010003A (es) Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
WO2010132757A3 (en) Antibacterial aminoglycoside analogs
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
MX2015000903A (es) Derivados de carbamato/urea.
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MY192545A (en) Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
CY1116274T1 (el) Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
TN2011000531A1 (en) 5- alkynyl - pyridines
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
PH12013500361A1 (en) Preventive or therapeutic agent for fibrosis
BRPI0820455B8 (pt) composição para agir sobre a síndrome metabólica
MY160300A (en) Acylbenzene derivative
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
MX2012001107A (es) Derivado de amida.
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
FI3433257T3 (fi) Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2016 BY SPRUSON + FERGUSON

Effective date: 20151104

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2017 BY SPRUSON + FERGUSON

Effective date: 20161031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2018 BY SPRUSON + FERGUSON

Effective date: 20171128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2019 BY SPRUSON + FERGUSON

Effective date: 20181113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2020 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20191108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2021 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20201030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2022 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20211029

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2023 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20221107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2024 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20231031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2025 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20241031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 NOV 2026 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20250902